Chapman Rowan E, a director at Natera, Inc. (NASDAQ:NTRA), has sold 1,767 shares of the company’s common stock. The shares were sold at a weighted average price of $170.24, with individual transaction prices ranging from $170.22 to $170.32. This sale, completed on December 10, 2024, amounted to a total value of approximately $300,808. The transaction occurs as Natera trades near its 52-week high of $175.63, having surged 185% over the past year and 48% in the last six months. Following this transaction, Rowan E holds 6,202 shares of Natera directly. According to InvestingPro analysis, the stock currently appears overvalued, with 14 additional exclusive insights available to subscribers through the comprehensive Pro Research Report.
In other recent news, Natera Inc (NASDAQ:). has reported significant developments. The company recently amended its agreement with Executive Chairman Dr. Rabinowitz, who will continue his role on an at-will basis, with an annual base salary set at half of the CEO’s base salary. Additionally, Natera faced a setback in a false advertising lawsuit against Guardant Health (NASDAQ:), but remains firm in its disagreement with the decision. Despite this, Natera reported a record Q3 revenue of $439.8 million, a 64% increase year-over-year, and conducted 137,000 oncology tests, marking a 54% increase from the previous year. The company’s gross margins reached a record high of 62%, leading to a revision of its full-year revenue guidance to between $1.61 billion and $1.64 billion. Analyst firms TD Cowen, Baird, and Jefferies have maintained favorable ratings on Natera’s stock and raised their price targets. These are recent developments that have emerged from the company’s operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
